Oncotype DX and Prosigna in breast cancer patients: A comparison study.
Cancer treatment and research communications（2021）
摘要
The agreement between ODX and Prosigna® is low, and this has management implications, especially when chemotherapy is needed.
更多查看译文
关键词
Breast cancer,OncotypeDx,Postmenopausal,Prosigna,Recurrence score
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要